ARTEMISMEDBSEArtemis Medicare Services LtdMediumNeutral
Announced Fri, 15 May · 15:31 IST

Transcript of Earnings Conference Call - Q4 and FY26

Mgmt Guided Margin ImprovementAnalyst Day Multiyear TargetsInvestor Communications View source PDF

ARTEMISMED · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-2.4%1-day move
₹280.33
prior close
₹280.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.5-0.3-1.1-1.5-2.4-0.1-0.3-3.1+2.9-1.3-8.0-7.8-3.5
Up moveDown movePending
AI summary

Artemis Medicare reported strong FY26 results with consolidated revenue of INR 1,081 crores (up 15.4% YoY), EBITDA of INR 218 crores (20.2% margin), and PAT of INR 104 crores (up 26.2%). Q4 FY26 revenue was INR 279 crores with EBITDA margin of 21.3%. The Gurugram flagship hospital operates at 64.6% occupancy with ARPOB of INR 84,571 (up 7.3% YoY). International patients contribute 30-31% of revenue despite West Asia tensions, growing 26.9%. The company received Green Building certification enabling 100 additional beds at Gurugram. Key expansion includes a 300-bed Raipur facility launching Q1 FY27 (150 beds initially) and a 650-bed South Delhi hospital by FY29 (capex INR 500 crores). Management guided that Gurugram margins will remain above 20% driven by case mix improvement, operational efficiency, and corporate cost leverage. Raipur is expected to incur INR 18-20 crores losses in FY27 before breakeven in 18 months, dragging consolidated margins by 1-1.5% temporarily.

Likely market impact

Strong growth trajectory with clear multiyear expansion roadmap. Short-term margin pressure from Raipur ramp-up is manageable and will normalize within 18 months. Board-approved INR 700 crores fundraising positions the company well for its 2,000-bed target by 2029.